CA.1aj.9

(redirected from carbonic anhydrase IX)

CA.1aj.9

A gene on chromosome 9p12 that encodes a carbonic anhydrase, a zinc metalloenzyme that catalyses the reversible hydration of carbon dioxide. Carbonic anhydrases participate in various biological processes, including respiration, calcification, maintaining acid-base balance and bone resorption, as well as producing aqueous humour, cerebrospinal fluid, saliva and gastric acid. CA9 is a transmembrane protein and the only known tumour-associated carbonic anhydrase isoenzyme, and may be involved in cell proliferation and transformation.

Molecular pathology
CA9 is expressed in all clear-cell type renal cell carcinomas, but is not expressed in normal kidney or most other normal tissues.
Mentioned in ?
References in periodicals archive ?
Carbonic anhydrase IX is a potential tumor marker that shows some promise for earlier detection of RCC.
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target.
Staining for S100, CD68, and D2-40 was weak and scattered in both components of the collision tumor, while vimentin, neuron-specific enolase (NSE), and carbonic anhydrase IX (CA IX) showed strong immunoreactivity in both HAB and RCC cells.
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Diagnostic implications of transcription factor Pax2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Presented preclinical data at the American Association of Immunology Conference demonstrating that active immunotherapy using Dendreon's proprietary Antigen Delivery Cassette(TM) technology with the antigen carbonic anhydrase IX (CA9), a well-validated and highly-expressed target in renal cell carcinoma, significantly prolonged survival in animal models.
Tumor levels of a third tumor protein regulated by HIF-1alpha, carbonic anhydrase IX (CA IX), were also decreased, consistent with HIF-1alpha inhibition.
SEATTLE and BOSTON, May 15 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced preclinical data demonstrating that active immunotherapy using Dendreon's proprietary Antigen Delivery Cassette(TM) technology with the antigen carbonic anhydrase IX (CA9), a well-validated and highly-expressed target in renal cell carcinoma (RCC), significantly prolonged survival in RCC animal models.
The staining profile with carbonic anhydrase IX is negative in most ChRCCs and when positive, it is usually patchy and seen in association with necrosis.
Immunohistochemistry: Carbonic Anhydrase IX Expression.
These entities can also be positive for PAX2, kidney-specific cadherin, carbonic anhydrase IX, and parvalbumin (3).

Full browser ?